Quantcast

Latest Nasal administration Stories

2014-08-04 08:27:48

Current Investors and Management Increase Support for OptiNose and the Company's Breakthrough New Product, OPN-375 YARDLEY, Pa., Aug. 4, 2014 /PRNewswire/ -- OptiNose, a specialty pharmaceutical company, announced today that it has completed a Series C-1 round of financing led by existing investors. Since obtaining Series C financing in 2010, OptiNose has successfully developed AVP-825, a product that, once approved, will be used for the treatment of migraines. OptiNose out-licensed...

2014-06-24 08:31:20

ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM) Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56(th) Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel...

2014-06-10 08:30:15

AVP-825, Using OptiNose's Patented Bi-Directional(TM) Breath Powered(TM) Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest Dose of Oral Sumatriptan YARDLEY, Pa., June 10, 2014 /PRNewswire/ -- OptiNose today announced that the COMPASS trial, a head-to-head comparison of the investigational treatment AVP-825 to sumatriptan tablets, currently the most widely used prescription medication for migraine, met...

2014-04-08 12:30:53

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/6d9skh/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The delivery of drugs to central nervous system (CNS)...

2014-01-30 08:32:21

AVP-825 uses novel Breath Powered(TM) drug delivery to treat migraine YARDLEY, Pa., Jan. 30, 2014 /PRNewswire/ -- A New Drug Application (NDA) was submitted on Monday January 27, 2014 to the U.S. Food and Drug Administration for AVP-825, a product using OptiNose's innovative closed-palate Breath Powered intranasal delivery system to deliver low-dose sumatriptan powder for the acute treatment of migraine. The NDA submission is based on a series of laboratory and clinical studies...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related